Sage Therapeutics, Inc. (SAGE) [Rocket]

Overview

Sage Therapeutics, Inc. (SAGE)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
08/11/2023	4	Form 4 - Statement of changes in beneficial ownership of securities:
08/08/2023	4	Greene Barry E (President and CEO) has filed a Form 4 on Sage Therapeutics, Inc.
08/07/2023	S-8	Form S-8 - Securities to be offered to employees in employee benefit plans:
08/07/2023	10-Q	Quarterly Report for the period ended June 30, 2023
08/07/2023	8-K	Quarterly results
07/10/2023	SC 13G/A	WELLINGTON MANAGEMENT GROUP LLP reports a 10.6% stake in Sage Therapeutics, Inc.
06/16/2023	4	Federer Jessica (Director) has filed a Form 4 on Sage Therapeutics, Inc.

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
Revenues	6.3	1,114.2	6.9	90.3	0.0	0.0	0.0	0.0
Revenue growth	-99.4%	16123.1%	-92.4%
Cost of goods sold	0.6	0.6	0.4	0.0	0.0	0.0	0.0	0.0
Gross profit	5.8	1,113.6	6.5	90.3	0.0	0.0	0.0	0.0
Gross margin	91.2%	99.9%	94.2%	100.0%
Selling, general and administrative	183.5	197.0	345.8	201.4	62.9
Research and development	283.2	292.7	368.8	282.1	210.3	120.8	69.4	24.1
General and administrative						39.4	25.3	9.7
EBIT	-460.9	624.0	-708.1	-393.2	-273.2	-160.2	-94.7	-33.8
EBIT margin	-7306.7%	56.0%	-10310.5%	-435.6%
Pre-tax income	-457.9	606.1	-680.2	-372.9	-270.1	-159.0	-94.5	-33.8
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-457.9	606.1	-680.2	-372.9	-270.1	-159.0	-94.5	-36.1
Net margin	-7258.9%	54.4%	-9904.5%	-413.1%

Diluted EPS	($7.80)	$11.43	($13.38)	($8.08)	($7.09)	($4.75)	($3.40)	($1.67)
Shares outstanding (diluted)	58.7	53.0	50.8	46.1	38.1	33.5	27.8	21.6

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.